You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 藥明生物(2269.HK)漲超3%創歷史新高 擬向Bayer購買生物藥原液製造工廠設施資產
格隆匯 12-22 10:55
格隆匯12月22日丨藥明生物(2269.HK)低開高走,盤中高見94港元創歷史新高,現報93.5港元,漲3.14%,暫成交3.56億港元,最新總市值3816億港元,該股今年迄今已累漲超1.8倍。藥明生物昨晚發公告稱,公司間接全資附屬公司Wu Xi Biologics Germany將向Bayer購買位於德國伍珀塔爾的生物藥原液製造工廠的設施資產,並計劃簽訂長期轉租協議和過渡服務合同,交易總金額約為1.5億歐元。董事認為,該等生物藥原液製造工廠將助力集團提供一流生物藥商業化產能。此外,拜耳和藥明生物均表示,此次交易尚待監管部門批准,預計將在2021年上半年完成。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account